Alembic Pharma Q2 FY27 Revenue Up 36% to ₹2,603 Cr

Alembic Pharmaceuticals reported strong consolidated financial results for Q2 FY27, with revenue from operations increasing by 36% year-on-year to ₹2,603 Cr. Profit After Tax (PAT) surged by 81% YoY to ₹335 Cr. The company's performance was driven by a significant 77% YoY growth in US Formulations, which reached ₹1,003 Cr, and a 39% YoY increase in API business to ₹436 Cr. The India Branded Business also showed resilience with 14% YoY growth to ₹725 Cr. Management highlighted strong execution across markets, particularly in the US, and expressed confidence in sustaining growth.